Marcus Chapman Net Worth

The estimated Net Worth of Marcus Chapman is at least $12.6 mil dollars as of 1 November 2019. Mr. Chapman owns over 12,000 units of Seres Therapeutics Inc stock worth over $12,600 and over the last 5 years he sold MCRB stock worth over $0. In addition, he makes $0 as Senior Vice President - Finance and Principal Financial and Accounting Officer at Seres Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Chapman MCRB stock SEC Form 4 insiders trading

Marcus has made over 1 trades of the Seres Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 12,000 units of MCRB stock worth $12,600 on 1 November 2019.

The largest trade he's ever made was exercising 12,000 units of Seres Therapeutics Inc stock on 1 November 2019 worth over $12,600. On average, Marcus trades about 3,000 units every 0 days since 2019. As of 1 November 2019 he still owns at least 12,000 units of Seres Therapeutics Inc stock.

You can see the complete history of Mr. Chapman stock trades at the bottom of the page.

Marcus Chapman biography

Marcus Chapman serves as Senior Vice President - Finance and Principal Financial and Accounting Officer of the Company. Since joining our company in March 2015, he has held positions of increasing seniority, most recently as our Senior Director of Finance from March 2015 to January 2018. Prior to joining our company, Mr. Chapman served in roles of increasing seniority from August 2007 to March 2015, culminating as Senior Director of Finance and Interim Head of Finance for Takeda Oncology (“Takeda”), the oncology business unit of Takeda Pharmaceuticals Co. Ltd. In these roles, Mr. Chapman oversaw finance functions supporting U.S. sales, U.S. and global marketing, operations, global medical affairs and manufacturing. Prior to Takeda, Mr. Chapman held senior roles at Clarion Healthcare Consulting and Strategic Decisions Group. He began his career at LaSalle Partners in their Investment Banking and Investment Management groups. Mr. Chapman received his B.A. in Economics from Wheaton College and his MBA from The Tuck School of Business at Dartmouth College.

How old is Marcus Chapman?

Marcus Chapman is 49, he's been the Senior Vice President - Finance and Principal Financial and Accounting Officer of Seres Therapeutics Inc since 2019. There are 15 older and 5 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.

What's Marcus Chapman's mailing address?

Marcus's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Seres Therapeutics Inc

Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., eHealth Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.

What does Seres Therapeutics Inc do?

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Complete history of Mr. Chapman stock trades at Seres Therapeutics Inc

Seres Therapeutics Inc executives and stock owners

Seres Therapeutics Inc executives and other stock owners filed with the SEC include:

• Eric Shaff,
  President, Chief Executive Officer, Director
• Eric D. Shaff M.B.A.,
  Pres, CEO & Director
• Thomas DesRosier,
  Chief Legal Officer, Executive Vice President and Secretary
• Matthew Henn,
  Executive Vice President, Chief Scientific Officer
• Thomas J. DesRosier,
  Chief Legal Officer, Exec. VP & Sec.
• Dr. David S. Ege Ph.D.,
  Exec. VP & Chief Technology Officer
• Richard Kender,
  Independent Director
• Kurt Graves,
  Independent Director
• Meryl Zausner,
  Independent Director
• Willard Dere,
  Independent Director
• Gregory Behar,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Stephen Berenson,
  Independent Chairman of the Board
• David Ege,
  Executive Vice President, Chief Technology Officer
• Jayne Gansler,
  Chief People Officer, Executive Vice President
• Terri Young,
  Executive Vice President, Chief Commercial and Strategy Officer
• Lisa von Moltke,
  Executive Vice President, Chief Medical Officer
• Paul Biondi,
  Independent Director
• Carlo Tanzi,
  Head of Investor Relations and Corporate Communications
• John Aunins,
  Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer
• Marcus Chapman,
  Senior Vice President - Finance and Principal Financial and Accounting Officer
• Dr. John G. Aunins Ph.D.,
  Sr. Advisor
• Dr. Matthew R. Henn Ph.D.,
  Exec. VP & Chief Scientific Officer
• David A. Arkowitz M.B.A.,
  Exec. VP, CFO & Head of Bus. Devel.
• James R. Weston,
  Sr. VP of Regulatory Affairs
• Jayne M. Gansler,
  Exec. VP & Chief People Officer
• Jeff York,
  VP of HR
• Noubar Flagship Ventures Fu...,
  
• Peter Barton Hutt,
  Director
• Michele Trucksis,
  See Remarks
• David N Cook,
  See Remarks
• Noubar Afeyan,
  Director
• Health Science Us Holdings,...,
  
• Lorence H. Kim,
  Director
• Wael Hashad,
  EVP & Chief Commercial Officer
• Teresa L. Young,
  See Remarks
• Paula Cloghessy,
  See Remarks
• Marella Thorell,
  See Remarks
• Roger Pomerantz,
  President and CEO
• Kevin Horgan,
  Chief Medical Officer and EVP
• Werner Cautreels,
  Director
• Noubar Flagship Ventures Fu...,
  
• Ventures Fund Iv General Pa...,
  
• Health Ltp Fund General Par...,
  
• David Arkowitz,
  Chief Financial Officer
• Health Ltp Fund General Par...,
  
• Claire Fraser,